Navigation Links
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
Date:12/13/2012

MONMOUTH JUNCTION, N.J., Dec. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling serious orphan lung diseases, today announced that the Company will be participating in the 31st Annual J.P. Morgan Healthcare Conference from January 7-10, 2013 at the Westin St. Francis Hotel in San Francisco.  Will Lewis, Insmed's President and CEO, will present a corporate overview on Thursday, January 10th at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). 

A live audio webcast of Mr. Lewis' presentation will be made available in the Investor section of Insmed's website, http://www.insmed.com where it will be archived for 90 days.

Insmed management will be available for one-on-one meetings with investors and analysts throughout the conference from January 7-10, 2013.  To schedule an appointment, contact Anne Marie Fields of LHA at 212-838-3777 or afields@lhai.com or contact your J.P. Morgan representative.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious orphan lung diseases through the development and commercialization of novel, targeted inhalation therapies in orphan patient populations with critical unmet needs. Insmed's lead candidate, ARIKACE®, is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). Following positive phase 2 results in CF patients, Insmed's p
'/>"/>

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Incorporated Provides Corporate Update
2. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
3. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
4. Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
5. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
(Date:8/27/2014)... -- Reportbuyer.com has added a new market research ... Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... similar amount of hype currently surrounds graphene, with ... water treatment, but is graphene the only solution? ... Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
Breaking Biology Technology:DTU researchers film protein quake for the first time 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... been proposed for regenerative medicine and tissue replacement after ... to efficiently develop into the desired specific cell type ... neurons now limits the potential clinical utility of ... within aggregates of embryonic stem cells via biodegradable microspheres ...
... Ill., April 9 Baxter Healthcare Corporation,today ... VitalShield,protective coating, the first needleless intravenous (IV) ... available for hospitals in the,United States and ... to kill on,average 99.9 percent or more ...
... April 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... its U.K. combination REOLYSIN(R) and carboplatin/paclitaxel,trial. Dr. ... Research, London,and the principal investigator for the ... Annual Conference of the British Society for ...
Cached Biology Technology:Method to deliver molecules within embryonic stem cells improves differentiation 2Method to deliver molecules within embryonic stem cells improves differentiation 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 3
(Date:8/27/2014)... listen carefully to someone, the first thing we do ... stop moving altogether. This strategy helps us hear better ... , This interplay between movement and hearing also has ... has long suggested that the brain,s motor cortex, which ... rise to our conscious perception of sound. , A ...
(Date:8/27/2014)... often depicted as giant, frightening beasts. But every creature ... a rock slab containing fossils of 24 very young ... group of hatchlings overseen by a caretaker, according to ... Penn,s Brandon P. Hedrick and Peter Dodson led the ... Natural History, where the specimen is held. Hedrick is ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... National Institutes of Health (NIH) announced today a new ... articles resulting from NIH-funded research. The policy ?the first ... release to the public manuscripts from research supported by ... of final publication. , These peer-reviewed, NIH-funded research publications ...
... Medical School, demonstrating how malaria parasites form mutations that ... the key to a new treatments for a disease ... , The scientists developed disease models using yeast and ... the anti-malarial drug, atovaquone. The study, featured as the ...
... for humans and most animals but not Australia's green-striped ... University of Queensland has found that unlike most animals, ... the green-striped burrowing frog is able to absorb nutrients ... than frogs that had eaten regularly. , "They can ...
Cached Biology News:NIH Calls on Scientists to Speed Public Release of Research Publications 2NIH Calls on Scientists to Speed Public Release of Research Publications 3Molecular models advance the fight against malaria 2A frog's life is food for thought 2A frog's life is food for thought 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: